Brief: Envision Trial Results Published In The Journal Of Urology Report 82.3% Duration Of Response 12 Months After Achieving Complete Response For UGN-102, Potentially First FDA-Approved Non-Surgical Treatment For LG-IR-NMIBC
28/10/2024 12:05
Oct 28 (Reuters) - Urogen Pharma Ltd UR8.F :
* ENVISION TRIAL RESULTS PUBLISHED IN THE JOURNAL OF UROLOGY
REPORT 82.3% DURATION OF RESPONSE 12 MONTHS AFTER ACHIEVING
COMPLETE RESPONSE FOR UGN-102, POTENTIALLY FIRST FDA-APPROVED
NON-SURGICAL TREATMENT FOR LG-IR-NMIBC
Source text: ID:nBwX04fBa
Further company coverage: UR8.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on UroGen Pharma
See all newsBrief: Urogen Submits NDA For Ugn-103, An Investigational Treatment Of Recurrent Lg-Ir-Nmibc
Reports 36-Month Duration Of Response Of 64.5% For ZUSDURI In Phase 3 Envision Trial
Brief: Journal Of Urology Publishes Envision Trial Results Showing 72.2% 24-Month Duration Of Response With Zusduri
Brief: Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Urogen Announces Refinanced Term Loan Agreement With Pharmakon Advisors